Trinity Biotech was founded in 1992 and listed on the NASDAQ market shortly after its formation. Through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products.

Today Trinity Biotech is listed on the NASDAQ Global Select Market, and has approximately 21 million American Depository Shares. The Company, which has its headquarters in Bray, Ireland, employs in excess of 570 people worldwide and markets its portfolio of over 400 products to customers in over 110 countries around the world.

Trinity Biotech’s growth to date has involved the following:

1994

MarAcquired Disease Detection International, Irvine, California, USA.

1996

JulLaunched Uni-Gold™ HIV and One-step test.

1997

FebAcquired Clark Laboratories, Jamestown, New York, USA. JulAcquired Centocor, Cambridge, UK.

1998

MarOpened 50,000 sq. ft. manufacturing facility in Bray, Ireland. JunAcquired Hormone & Drugs of Abuse from Diatech, Boston, USA. JulAcquired Macra® Lp(a) from Strategic Diagnostics Inc., USA. SepAcquired HIV product line from Cambridge Diagnostics, USA. OctAcquired MicroTrak® product line from Dade Behring, USA. 2000 MarAcquired MarDx® Diagnostics, Inc., Carlsbad, California, USA. DecAcquired assets and goodwill of Bartels Inc., Oregon, USA.

2001

OctEstablishment of Trinity Biotech German sales and marketing subsidiary DecAcquired Biopool, Ventura, California, USA.

2002

AugAcquired coagulation division of Sigma Diagnostics, USA. OctEstablishment of Trinity Biotech UK sales & marketing subsidiary. DecAcquired Specialty Clinical Chemistry, Sigma Diagnostics, USA. 2003 DecFDA clearance for Uni-Gold™ Recombigen® HIV test.

2004
AprAcquired Adaltis US, Inc. AprAcquires Fitzgerald Industries International, Mass, USA. NovReceived US CLIA Waiver for Uni-Gold™ Recombigen® HIV Test. 2005 MarAcquired Research Diagnostics Inc., Flanders, New Jersey, USA. JulAcquired Primus Corporation of Kansas City, Missouri, USA.

2006
JunAcquired coagulation division of bioMerieux, Lyon, France.

2010
MayAcquisition by Stago of the Trinity Biotech coagulation division.

2011
JanAcquired Phoenix Bio-tech Corporation MayLaunch of Premier Hb9210

2012
MarAcquisition of Fiomi Diagnostics AB

2013
JulAcquisition of Immco Diagnostics Inc., Buffalo, NY, USA JulAcquisition of the blood bank screening business of Lab21 ltd.

Captia - Measles IgM EIA Tests Kit - Brochure